MaxCyte Director Retires after 18 Years

By Bobby Samwell • Saturday, December 28 10:14 • Permanent Link

Maxcyte, Inc. (NASDAQ: MXCT; LSE: MXCT) has announced the retirement of Art Mandell from his position as a member of the board of directors, effective December 31, 2024. Mandell, who has served on the board since 2006, has played a key role in the company's growth and strategic direction.

During Mandell's tenure, Maxcyte achieved several significant milestones, including its initial public offering on the UK AIM Exchange and US NASDAQ listing, the launch of its flagship Expert™ platform, the signing of 29 strategic platform licenses with cell and gene therapy biotech companies, and support for the industry's first FDA-approved CRISPR edited non-viral cell therapy.

Following Mandell's retirement, Maxcyte will have nine directors. Richard Douglas, the Chairman of the Board, expressed gratitude for Mandell's exceptional leadership and valuable contributions, emphasizing his instrumental role in positioning Maxcyte as a leader in cell engineering.

In response, Mandell expressed pride in the company's accomplishments and confidence in its future, highlighting Maxcyte's commitment to providing highly differentiated technology solutions that enable the development of novel cell and gene therapies.

Maxcyte is known for pursuing cell engineering excellence to maximize the potential of cells to improve patients' lives. The company's Expert™ platform, based on its Flow Electroporation® technology, aims to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines.

The Expert family of products includes four instruments (ATx™, STx™, GTx™, and VLx™), a portfolio of proprietary related processing assemblies or disposables, and software protocols, all supported by a robust worldwide intellectual property portfolio.

Following these announcements, the company's shares moved 1.5%, and are now trading at a price of $4.13. For the full picture, make sure to review MaxCyte's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.